Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml(University of Pennsylvania), Robert I. Haddad(Georgetown University), Tanguy Y. Seiwert(Georgetown University), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), Francis P. Worden(Georgetown University), Lori J. Wirth(Massachusetts General Hospital), Erminia Massarelli(The University of Texas MD Anderson Cancer Center), Amy Meister(Georgetown University), Nabil F. Saba(Emory University), Stephen V. Liu(Georgetown University), Xinxin Shu(Georgetown University), Hyunseok Kang(Johns Hopkins University), Steven Powell(Georgetown University), Jared Weiss(Georgetown University), Jill Gilbert(Cancer Clinic), Michael K. Gibson(Vanderbilt University), Jonathan D. Cheng(Princeton University), David G. Pfister(Memorial Sloan Kettering Cancer Center)
Cited by 653
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k